

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This is a voluntary announcement made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide its shareholders and potential investors with information in relation to the latest developments regarding the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that the Board resolved to repurchase shares of the Company in the open market from time to time subject to market conditions, pursuant to the share repurchase mandate approved by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting held on May 25, 2023 (the “**2022 AGM**”) (the “**Share Repurchase Mandate**”). Pursuant to the Share Repurchase Mandate, the Company is allowed to repurchase up to 10% of the aggregate number of Shares in issue as at the 2022 AGM, i.e. up to 67,885,680 Shares.

The Company shall conduct the repurchases by exercising its powers under the Share Repurchase Mandate, and in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Companies Act (As Revised) of the Cayman Islands, the Codes on Takeovers and Mergers and Share Buy-backs and all other applicable laws and regulations to which the Company is subject.

The Directors have no intention to exercise the Share Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the minimum percentage as prescribed by the Stock Exchange or give rise to an obligation to make a general offer to the shareholders under Rules 26 and 32 of the Takeovers Code.

The Board believes that the share repurchase will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to its Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the share repurchase while maintaining a solid financial position.

Shareholders and potential investors should note that the implementation of the on-market share repurchase by the Company will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any repurchases or whether the Company will make any repurchases at all. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, June 20, 2024

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Dr. Zhiyun YU, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.